Compare · ABEO vs CERE
ABEO vs CERE
Side-by-side comparison of Abeona Therapeutics Inc. (ABEO) and Cerevel Therapeutics Holdings Inc. (CERE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABEO and CERE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- CERE is the larger of the two at $3.50B, about 11.2x ABEO ($311.2M).
- ABEO has hit the wire 5 times in the past 4 weeks while CERE has been quiet.
- CERE has more recent analyst coverage (19 ratings vs 7 for ABEO).
- Company
- Abeona Therapeutics Inc.
- Cerevel Therapeutics Holdings Inc.
- Price
- $5.39-1.28%
- $44.97+0.81%
- Market cap
- $311.2M
- $3.50B
- 1M return
- -6.75%
- -
- 1Y return
- -17.58%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 0
- Recent ratings
- 7
- 19
Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
Cerevel Therapeutics Holdings Inc.
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Latest ABEO
- Abeona Therapeutics Inc. filed SEC Form 8-K: Other Events
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Alvino Mark gifted 500 shares, decreasing direct ownership by 0.64% to 77,065 units (SEC Form 4)
- Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
- Director Alvino Mark sold $35,463 worth of shares (6,500 units at $5.46), decreasing direct ownership by 8% to 77,565 units (SEC Form 4)
- Director Crombez Eric sold $144,636 worth of shares (26,143 units at $5.53) as part of a pre-agreed trading plan, decreasing direct ownership by 41% to 37,313 units (SEC Form 4)
- SEC Form 10-Q filed by Abeona Therapeutics Inc.
- Abeona Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
- Chief Commercial Officer Vasanthavada Madhav sold $33,073 worth of shares (5,548 units at $5.96), decreasing direct ownership by 2% to 313,071 units (SEC Form 4) to satisfy withholding obligation
Latest CERE
- Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
- SEC Form 15-12G filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- Former 10% Owner Pfizer Inc closing all direct ownership in the company (SEC Form 4)
- Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.
- Director Bain Capital Investors Llc returned 65,679,781 shares to the company (SEC Form 4)
- Director Gordon Christopher R returned 65,693,524 shares to the company, closing all direct ownership in the company (SEC Form 4)